Thomas Jefferson University

Russell Schilder

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentMedical Oncology - Thomas Jefferson University
Address1025 Walnut Street
Philadelphia PA 19107
Phone215-503-3057
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R03CA058334     (SCHILDER, RUSSELL J)Sep 30, 1992 - Sep 29, 1995
    NIH
    PBSC SUPPORT OF HIGH-DOSE THERAPY FOR OVARIAN CANCER
    Role: Principal Investigator
    UG1CA233341     (JOHNSON, JENNIFER)Mar 5, 2019 - Feb 29, 2032
    NIH
    Sidney Kimmel Cancer Center LAPS Institutional Collaboration
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schilder RJ, Rasco D, Sharma MR. An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors. Neoplasia. 2025 03; 61:101133. PMID: 39914170.
      Citations:    
    2. Mayadev J, Zamarin D, Deng W, Lankes HA, Pesci G, Kim H, Chino JP, Banbury B, Sherry N, Sharon E, Ghamande SA, Ferguson C, Mell L, Holman L, Mathews C, O'Malley D, Olawaiye A, Hopp E, Leath C, Copeland L, Mannel R, O'Cearbhaill R, Aghajanian C, Schilder RJ. Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553. PMID: 39788967.
      Citations:    
    3. Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Curr Probl Cancer. 2021 12; 45(6):100734. PMID: 33865615.
      Citations:    
    4. Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515. PMID: 33610319.
      Citations:    
    5. Duska LR, Krasner CN, O'Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, Zamboni WC, Lucas AT, Supko JG, Schilder RJ. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2021 03; 160(3):688-695. PMID: 33390325.
      Citations:    
    6. Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande SA, Lin YG, Schilder RJ, Birrer MJ, Kast WM. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 11 01; 26(21):5621-5630. PMID: 32816895.
      Citations:    
    7. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, F?rkkil? A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968. PMID: 32553118.
      Citations:    
    8. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 04; 21(4):531-540. PMID: 32105622.
      Citations:    
    9. Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020 Jan 01; 6(1):92-99. PMID: 31774464.
      Citations:    
    10. Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol. 2020 Jan 01; 6(1):100-107. PMID: 31697308.
      Citations:    
    11. Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer. 2020 05; 30(5):701-704. PMID: 31871115.
      Citations:    
    12. Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22. PMID: 31708167.
      Citations:    
    13. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428. PMID: 31623857.
      Citations:    
    14. Falchook G, Coleman RL, Schilder RJ. Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):910-911. PMID: 31021370.
      Citations:    
    15. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. PMID: 30347019.
      Citations:    
    16. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, Johnson JM. Metformin as a Therapeutic Target in Endometrial Cancers. Front Oncol. 2018; 8:341. PMID: 30211120.
      Citations:    
    17. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57. PMID: 29122619.
      Citations:    
    18. Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290. PMID: 28802766.
      Citations:    
    19. Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol. 2017 09; 146(3):484-490. PMID: 28698009.
      Citations:    
    20. Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242. PMID: 28341300.
      Citations:    
    21. Gilani MA, Williams NL, Giordano C, Rosenblum N, Shi W, Anne P, Schilder RJ. Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature. Open J Obstet Gynecol. 2016 Aug; 6(9):544-552. PMID: 31552146.
      Citations:    
    22. Pathak HB, Zhou Y, Sethi G, Hirst J, Schilder RJ, Golemis EA, Godwin AK. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One. 2015; 10(12):e0144126. PMID: 26637171.
      Citations:    
    23. Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Mol Cancer Ther. 2015 Nov; 14(11):2569-75. PMID: 26333381.
      Citations:    
    24. Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015; 2015:341723. PMID: 26075229.
      Citations:    
    25. Eldredge-Hindy HB, Eastwick G, Anne PR, Rosenblum NG, Schilder RJ, Chalian R, Zibelli AM, Kim CH, Den R. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy. 2014 Oct; 6(3):262-70. PMID: 25337127.
      Citations:    
    26. Vergote I, Schilder RJ, Pippitt CH, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct; 135(1):25-33. PMID: 25019569.
      Citations:    
    27. Sama AR, Schilder RJ. Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management. Int J Womens Health. 2014; 6:149-57. PMID: 24511245.
      Citations:    
    28. Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014 Mar; 132(3):526-30. PMID: 24361733.
      Citations:    
    29. Skwara AJ, Schilder RJ, Zibelli A, Rosenblum NG. Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report. Gynecol Oncol Case Rep. 2013; 6:7-9. PMID: 24371706.
      Citations:    
    30. Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, Testa JR, Kimura T. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther. 2013 Jul; 12(7):1367-77. PMID: 23615631.
      Citations:    
    31. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94. PMID: 23438670.
      Citations:    
    32. Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2014 Jan 30; 33(5):539-49. PMID: 23334327.
      Citations:    
    33. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91. PMID: 23321064.
      Citations:    
    34. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1339-49. PMID: 23138163.
      Citations:    
    35. Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61. PMID: 22960004.
      Citations:    
    36. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50. PMID: 22885469.
      Citations:    
    37. Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012 Oct; 127(1):63-9. PMID: 22772063.
      Citations:    
    38. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4. PMID: 22710075.
      Citations:    
    39. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26. PMID: 21752435.
      Citations:    
    40. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8. PMID: 21329967.
      Citations:    
    41. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-a5?1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9. PMID: 21276608.
      Citations:    
    42. Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):82-113. PMID: 21233246.
      Citations:    
    43. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41. PMID: 21495215.
      Citations:    
    44. Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, Oza AM. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer. 2010 Jul; 20(5):787-93. PMID: 20847613.
      Citations:    
    45. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20. PMID: 19712963.
      Citations:    
    46. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009 Sep 01; 15(17):5404-13. PMID: 19690197.
      Citations:    
    47. Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jul; 19(5):929-33. PMID: 19574787.
      Citations:    
    48. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009 Apr; 36(2):112-25. PMID: 19332246.
      Citations:    
    49. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr; 113(1):21-7. PMID: 19162309.
      Citations:    
    50. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2008 Jul 10; 26(20):3418-25. PMID: 18612157.
      Citations:    
    51. Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul; 6(6):594-622. PMID: 18597713.
      Citations:    
    52. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2008 Aug; 110(2):140-5. PMID: 18554700.
      Citations:    
    53. von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct; 19(10):1802-9. PMID: 18497430.
      Citations:    
    54. Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May-Aug; 5(3-4):137-49. PMID: 18820368.
      Citations:    
    55. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008 Mar 01; 14(5):1291-5. PMID: 18316546.
      Citations:    
    56. Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I, Molina A. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007 Oct; 22(5):684-91. PMID: 17979571.
      Citations:    
    57. Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Sep; 7(8):514-7. PMID: 18021468.
      Citations:    
    58. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007 Jul 15; 13(14):4261-70. PMID: 17634556.
      Citations:    
    59. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007 Jul 10; 25(20):2894-901. PMID: 17617520.
      Citations:    
    60. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 May 01; 109(9):1804-10. PMID: 17380530.
      Citations:    
    61. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007 May; 5(5):474-96. PMID: 17509252.
      Citations:    
    62. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi DE. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol. 2007; 29(4):289-99. PMID: 17641413.
      Citations:    
    63. Darcy KM, Schilder RJ. Relevant molecular markers and targets. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S6-S13. PMID: 17034839.
      Citations:    
    64. Martin L, Schilder RJ. Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. J Natl Compr Canc Netw. 2006 Oct; 4(9):955-66. PMID: 17020672.
      Citations:    
    65. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32. PMID: 16896006.
      Citations:    
    66. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Apr; 47(4):629-36. PMID: 16690521.
      Citations:    
    67. Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moore JO, Schilder RJ, Weiss L, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Mar; 4(3):210-30. PMID: 16507269.
      Citations:    
    68. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):732-55. PMID: 16316611.
      Citations:    
    69. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005 Aug 01; 11(15):5539-48. PMID: 16061871.
      Citations:    
    70. Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Curr Treat Options Oncol. 2005 Mar; 6(2):115-20. PMID: 15717993.
      Citations:    
    71. Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Jan; 96(1):67-71. PMID: 15589582.
      Citations:    
    72. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005 Jan; 96(1):103-7. PMID: 15589587.
      Citations:    
    73. Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma. Haematologica. 2004 Dec; 89(12):1484-91. PMID: 15590399.
      Citations:    
    74. Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma. 2004 Dec; 5(3):202-4. PMID: 15636698.
      Citations:    
    75. Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer. 2004 Nov 01; 101(9):2034-41. PMID: 15455357.
      Citations:    
    76. Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2004 Oct; 5 Suppl 1:S16-21. PMID: 15498145.
      Citations:    
    77. Schilder RJ, Blessing JA, Pearl ML, Rose PG. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Invest New Drugs. 2004 Aug; 22(3):343-9. PMID: 15122083.
      Citations:    
    78. Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2004 Aug; 19(4):478-81. PMID: 15453962.
      Citations:    
    79. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004 Jun 15; 103(12):4429-31. PMID: 15016644.
      Citations:    
    80. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004 Jan; 5(1):19-24. PMID: 14749123.
      Citations:    
    81. Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 Jan; 34(1 Suppl 1):4-9. PMID: 14762738.
      Citations:    
    82. Armstrong DK, Blessing JA, Look KY, Schilder R, Nunez ER. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Invest New Drugs. 2003 Aug; 21(3):373-7. PMID: 14578687.
      Citations:    
    83. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-L?pez AJ, Witzig TE, White CA. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003 Apr; 18(2):165-78. PMID: 12804042.
      Citations:    
    84. Schilder RJ, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2003 Jan; 88(1):3-8. PMID: 12504619.
      Citations:    
    85. Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep; 50(3):243-50. PMID: 12203107.
      Citations:    
    86. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-L?pez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15; 99(12):4336-42. PMID: 12036859.
      Citations:    
    87. Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15; 19(4):1021-9. PMID: 11181665.
      Citations:    
    88. Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15; 19(4):1183-94. PMID: 11181685.
      Citations:    
    89. Berman E, Clift RA, Copelan EA, Emanuel PD, Erba HP, Glenn MJ, Greenberg PL, Jones RJ, O'Brien S, Saba HI, Schilder R, Snyder DS, Soiffer RJ, Tallman MS, Wetzler M, Ravandi-Kashani F, Kantarjian H, Talpaz M. NCCN Practice Guidelines for Chronic Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):229-40. PMID: 11195415.
      Citations:    
    90. Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Feb; 76(2):204-7. PMID: 10637071.
      Citations:    
    91. Schilder RJ, Goldberg M, Millenson MM, Movsas B, Rogatko A, Rogers B, Langer CJ. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer. 2000 Jan; 27(1):37-45. PMID: 10672782.
      Citations:    
    92. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-L?pez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec; 17(12):3793-803. PMID: 10577851.
      Citations:    
    93. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-L?pez AJ. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3281s-3286s. PMID: 10541376.
      Citations:    
    94. Schilder R. Rituximab immunotherapy. Cancer Biother Radiopharm. 1999 Aug; 14(4):237-40. PMID: 10850309.
      Citations:    
    95. Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol. 1999 Jul; 17(7):2198-207. PMID: 10561276.
      Citations:    
    96. Boente MP, Schilder R, Ozols RF. Gynecological cancers. Cancer Chemother Biol Response Modif. 1999; 18:418-34. PMID: 10800496.
      Citations:    
    97. Smith MR, Xie T, Joshi I, Schilder RJ. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Br J Haematol. 1998 Sep; 102(4):1090-7. PMID: 9734662.
      Citations:    
    98. Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Semin Oncol. 1998 Jun; 25(3):349-55. PMID: 9633847.
      Citations:    
    99. Maloney DG, Grillo-L?pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15; 90(6):2188-95. PMID: 9310469.
      Citations:    
    100. Essayan DM, Schilder R, Kagey-Sobotka A, Jenkens MK, Korzeniowski O, Lichtenstein LM, King ED. Anaphylaxis during autologous peripheral blood progenitor cell infusion. Bone Marrow Transplant. 1997 Apr; 19(7):749-52. PMID: 9156255.
      Citations:    
    101. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997 Jan; 15(1):177-86. PMID: 8996140.
      Citations:    
    102. Boente MP, Schilder R, Ozols RF. Gynecologic cancers. Cancer Chemother Biol Response Modif. 1997; 17:536-61. PMID: 9551230.
      Citations:    
    103. Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. J Clin Oncol. 1996 Apr; 14(4):1275-81. PMID: 8648384.
      Citations:    
    104. Schaebler DL, Schilder RJ, Young RC. Gynecological malignancies. Cancer Chemother Biol Response Modif. 1996; 16:564-91. PMID: 8639401.
      Citations:    
    105. Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 1995 Aug 01; 55(15):3286-94. PMID: 7614463.
      Citations:    
    106. Kotz KW, Schilder RJ. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer. Semin Oncol. 1995 Jun; 22(3):250-62. PMID: 7777869.
      Citations:    
    107. Schilder RJ. Molecular markers and stem-cell transplants: are they made for each other? J Clin Oncol. 1995 May; 13(5):1052-4. PMID: 7738610.
      Citations:    
    108. Schilder RJ, Boente MP, Corn BW, Lanciano RM, Young RC, Ozols RF. The management of early ovarian cancer. Oncology (Williston Park). 1995 Feb; 9(2):171-82; discussion 185-7. PMID: 8771099.
      Citations:    
    109. von Mehren M, Giantonio BJ, McAleer C, Schilder R, McPhillips J, O'Dwyer PJ. Phase I trial of ilmofosine as a 24 hour infusion weekly. Invest New Drugs. 1995; 13(3):205-10. PMID: 8729947.
      Citations:    
    110. Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schilder RJ, Litam PP, Himpler BS, McAleer C, Wright J, Barbhaiya RH, et al. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5. Clin Cancer Res. 1995 Jan; 1(1):105-11. PMID: 9815892.
      Citations:    
    111. Haas NB, Schilder RJ, Nash S, Weiner LM, Catalano RC, Ozols RF, O'Dwyer PJ. A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. Invest New Drugs. 1995; 13(3):229-33. PMID: 8729951.
      Citations:    
    112. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 1994 Feb 01; 54(3):709-17. PMID: 8306332.
      Citations:    
    113. Schaebler DL, Schilder RJ, Young RC. Gynecologic malignancies. Cancer Chemother Biol Response Modif. 1994; 15:555-80. PMID: 7779599.
      Citations:    
    114. Schilder RJ, Scher RM, Young RC. Gynecologic malignancies. Cancer Chemother Biol Response Modif. 1993; 14:530-56. PMID: 8312118.
      Citations:    
    115. O'Dwyer PJ, Hudes GR, Walczak J, Schilder R, LaCreta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. Cancer Res. 1992 Dec 15; 52(24):6746-53. PMID: 1458462.
      Citations:    
    116. Schilder RJ, Young RC. Management of early-stage ovarian cancer. Hematol Oncol Clin North Am. 1992 Aug; 6(4):867-77. PMID: 1500390.
      Citations:    
    117. O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992 Aug; 10(8):1352-8. PMID: 1634926.
      Citations:    
    118. Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol. 1992; 29(4):305-8. PMID: 1537077.
      Citations:    
    119. Schilder RJ, Godfrey SA, Young RC. Gynecological malignancies. Cancer Chemother Biol Response Modif. 1992; 13:541-64. PMID: 1327047.
      Citations:    
    120. Schilder RJ, Ozols RF. New therapies for ovarian cancer. Cancer Invest. 1992; 10(4):307-15. PMID: 1352730.
      Citations:    
    121. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991 Nov 15; 51(22):6059-65. PMID: 1933869.
      Citations:    
    122. Hudes GR, Ozols RF, Schilder RJ. Genitourinary cancer. Cancer Chemother Biol Response Modif. 1991; 12:509-48. PMID: 1718377.
      Citations:    
    123. Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ, Ozols RF, Fojo AT, Hamilton TC. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer. 1990 Mar 15; 45(3):416-22. PMID: 2307530.
      Citations:    
    Schilder's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (430)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _